Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Paragon CareASX:PGC +3.85%49 EV-to-EBIT is 78.48 as of Aug. 15, 2026, which is 664% above its 10-year median of 10.27. GuruFocus rates ASX:PGC with a GF Score™ of 49/100 and a GF Value™ of A$0.40 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 96 Medical Distribution companies, Paragon Care ranks worse than 95.83% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Paragon Care's Enterprise Value for the quarter that ended in Dec. 2025 was A$723 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paragon Care's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paragon Care EV-to-EBIT Related Terms
Paragon Care EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Paragon Care's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Paragon Care's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Paragon Care EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Paragon Care's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Paragon Care's EV-to-EBIT falls into.
Paragon Care's current Enterprise Value is A$591 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Paragon Care's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Paragon Care (ASX:PGC) has a EV-to-EBIT of 78.48 as of Aug. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Paragon Care and its competitors. This is 664% above median its historical median of 10.27. According to the industry distribution chart, Paragon Care ranks #92 out of 96 companies in the Medical Distribution industry, placing it in the top 95.8%.
Is Paragon Care's EV-to-EBIT too high?
Paragon Care's current EV-to-EBIT of 78.48 is 664% above median its 10-year median of 10.27. The Medical Distribution industry median EV-to-EBIT is 11.90. Paragon Care's value of 78.48 is 559.8% above this industry median. Based on the distribution chart, Paragon Care ranks #92 out of 96 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Paragon Care has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Paragon Care's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Paragon Care ranks #92 out of 96 companies for EV-to-EBIT. This places Paragon Care in the lower half of its industry. The industry median EV-to-EBIT is 11.90. Paragon Care's value of 78.48 is 559.8% above this benchmark. While the company's 10-year median is 10.27 vs. the industry median of 11.90, Paragon Care has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.90, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Paragon Care's current EV-to-EBIT of 78.48 is 559.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Paragon Care and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Paragon Care's current EV-to-EBIT is 78.48, which is 664% above median its own 10-year median of 10.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Paragon Care stock overvalued right now?
Based on GuruFocus' analysis, Paragon Care (ASX:PGC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.40, compared to a current price of A$0.14 — trading 66.3% below its estimated fair value. The current EV-to-EBIT is 78.48, which is 664% above median its 10-year median of 10.27 and 559.8% above the Medical Distribution industry median of 11.90. Paragon Care's overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Paragon Care (ASX:PGC), the current EV-to-EBIT is 78.48 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Paragon Care (ASX:PGC) Overvalued in 2026?
Based on GuruFocus' analysis, Paragon Care stock appears to be undervalued.
The current stock price of A$0.14 is trading 66.3% below its estimated GF Value™ of A$0.40.
GuruFocus considers Paragon Care to be Possible Value Trap.
Key valuation signals for ASX:PGC:
EV-to-EBIT: 78.48 (664% above median its 10-year median of 10.27)
GF Value™: A$0.40 vs. price of A$0.14 (66.3% below fair value)
Industry Position: 559.8% above the Medical Distribution median (#92 of 96)
No single metric tells the full story. See the ASX:PGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Paragon Care Ltd is a medical device company. The company provides medical equipment, devices, and consumables medical products to the healthcare market. The company provides solutions to various healthcare markets, aged care, and veterinary markets. The group is organized into two operating segments: ParagonCare and CH2 Holdings and the majority of its revenues are generated from the CH2 Holdings segment engaged in the distribution of pharmaceuticals, medical consumables, nutritional, and over-the-counter products to the healthcare market.
49GF Score
Get the complete analysis for ASX:PGC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PGC has been successfully added to your 
